ANNOVIS BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.28 USD | -59.58% |
|
-36.64% | -61.07% |
| 09:56pm | Sector Update: Health Care Stocks Edge Higher Late Afternoon | MT |
| 09:02pm | Top Midday Decliners | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 198M 271M |
|---|---|---|---|---|---|
| Net income 2024 * | -34M -46.44M | Net income 2025 * | -58M -79.22M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 105M 144M | Net cash position 2025 * | 53.8M 73.48M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-6.47
x | P/E ratio 2025 * |
-6.23
x | Employees | 11 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.41% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -60.97% | ||
| 1 week | -36.64% | ||
| Current month | -38.82% | ||
| 1 month | -39.13% | ||
| 3 months | -36.03% | ||
| 6 months | -10.67% | ||
| Current year | -61.07% |
1 week
5.23
20.00
1 month
5.2320.00
Current year
5.2320.00
1 year
5.2322.49
3 years
5.23132.00
5 years
2.42132.00
10 years
2.42132.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 73 | 08-04-30 | |
Henry Hagopian
DFI | Director of Finance/CFO | 56 | 22-08-28 |
Melissa Gaines
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Hoffman
CHM | Chairman | 73 | 13-12-31 |
| Founder | 73 | 08-04-30 | |
Reid McCarthy
BRD | Director/Board Member | 70 | 21-04-08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 7.28 | -59.58% | 9 577 066 |
| 24-04-26 | 18.01 | +32.43% | 1,059,644 |
| 24-04-25 | 13.6 | +6.75% | 330,431 |
| 24-04-24 | 12.74 | +7.24% | 490,353 |
| 24-04-23 | 11.88 | +3.39% | 226,539 |
Delayed Quote Nyse, April 29, 2024 at 04:00 pm
More quotes
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimerâs disease (AD), Parkinsonâs disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
18.01
USD
Average target price
35.4
USD
Spread / Average Target
+96.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -61.07% | 198M | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- ANVS Stock
